Compare SDA & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SDA | ICCC |
|---|---|---|
| Founded | 2007 | 1982 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.8M | 93.1M |
| IPO Year | 2022 | 1995 |
| Metric | SDA | ICCC |
|---|---|---|
| Price | $0.52 | $9.58 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $4.75 | N/A |
| AVG Volume (30 Days) | ★ 409.0K | 20.2K |
| Earning Date | 04-28-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 53.85 |
| EPS | N/A | ★ 0.41 |
| Revenue | N/A | ★ $26,493,169.00 |
| Revenue This Year | $12.01 | N/A |
| Revenue Next Year | $15.55 | N/A |
| P/E Ratio | ★ N/A | $24.02 |
| Revenue Growth | N/A | ★ 51.64 |
| 52 Week Low | $0.42 | $4.52 |
| 52 Week High | $2.78 | $12.10 |
| Indicator | SDA | ICCC |
|---|---|---|
| Relative Strength Index (RSI) | 39.02 | 37.52 |
| Support Level | $0.47 | $9.55 |
| Resistance Level | $0.86 | $10.75 |
| Average True Range (ATR) | 0.09 | 0.25 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 47.80 | 10.76 |
SunCar Technology Group Inc operates digital automotive aftersales market service platform and vehicle insurance technology platform. It develops and operates online platforms that connect drivers in China with a range of aftermarket automotive services and insurance coverage options from a nationwide network of service providers. These comprehensive digital systems are built on SunCar's multi-tenant, cloud-based platform. Revenues from its continuing operations are mainly generated from providing auto eInsurance services, technology services, and auto services.
ImmuCell Corp is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. Its product, First Defense, utilizes hyperimmunized bovine colostrum to provide pathogen-specific antibodies and other bioactive components. First Defense is designed to provide Immediate Immunity through orally delivered antibodies against the principal viral and bacterial causes of neonatal calf diarrhea (scours), including Escherichia coli (E.coli), bovine coronavirus, and bovine rotavirus. It has two operating segments: Scours and Mastitis. It derives the majority of the revenue from the Scours segment that consists of the First Defense product line.